Different membrane expression of CD11b and CD14 on blood neutrophils following in vivo administration of myeloid growth factors.
During the administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) or granulocyte-macrophage CSF (rhGM-CSF) we studied the early and late changes of membrane antigen density on neutrophils. RhG-CSF and rhGM-CSF both caused an early transient reduction in blood neutrophilic granulocyte-concentration within the first 30 min after treatment followed by a marked later increase during the subsequent 24 h. During the early neutropenia quantitative flow cytometry showed an associated marked increase in the density of membrane CD11b from 169 x 10(3) before to 568 x 10(3) A.U. per cell induced by rhGM-CSF but a non-significant change by rhG-CSF, suggesting that different mechanisms may be responsible for the transient neutropenia. The subsequent neutrophil granulocytosis was followed by a significantly (P < 0.05) increased density of the CD14 antigen from 6.1 x 10(3) before to 15.9 x 10(3) A.U. per cell during treatment with rhG-CSF, but not by rhGM-CSF administration. These results demonstrate that the two cytokines may affect the function of neutrophilic granulocytes in different ways. The increased expression of CD11b could explain some of the side-effects during treatment with rhGM-CSF. The upregulation of CD14 induced by rhG-CSF may be clinically relevant, as CD14 is an opsonic receptor for lipopolysaccharide binding proteins, acting in the defence against Gram-negative bacterial infections.
Hansen
P B
PB
Department of Internal Medicine and Haematology L, University of Copenhagen, Herlev Hospital, Denmark.
Kjaersgaard
E
E
Johnsen
H E
HE
Gram
J
J
Pedersen
M
M
Nikolajsen
K
K
Hansen
N E
NE
D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000032:analysis / Q000187:drug effects*; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis / Q000187:drug effects*; D001853:Bone Marrow / Q000276:immunology; D018845:CD11 Antigens; D002462:Cell Membrane / Q000276:immunology; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology*; D006801:Humans; D007700:Kinetics; D007958:Leukocyte Count / Q000187:drug effects; D018950:Lipopolysaccharide Receptors; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000276:immunology*; D011994:Recombinant Proteins / Q000494:pharmacology
D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D018845:CD11 Antigens; D018950:Lipopolysaccharide Receptors; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor